Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: Novel opportunities for drug combinations to overcome resistance

Haematologica

Volumn 97, Issue 2, 2012, Pages 157-159

  Hantschel, Oliver ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; GNF 2; GNF 5; IMATINIB; MYRISTIC ACID; NILOTINIB; PROTEIN SH2; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; GAIN OF FUNCTION MUTATION; HUMAN; MYRISTYLATION; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PROTEIN PHOSPHORYLATION;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PYRIMIDINES;

EID: 84856460186     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.061812     Document Type: Editorial

References (19)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-56.
2. O'Hare T, Eide CA, Deininger MW. BCR-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242-9.
3. Hochhaus A. Educational session: managing chronic myeloid leukemia as a chronic disease. Hematology Am Soc Hematol Educ Program. 2011;2011:128-35.
4. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112(6):859-71.
5. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, et al. A Myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 2003;112(6):845-57.
6. Hantschel O, Superti-Furga G. Regulation of the c-Abl and BCR-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33-44.
7. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of BCR-abl-dependent cell proliferation. Nat Chem Biol. 2006;2(2):95-102.
8. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, et al. Kinase domain mutants of BCR-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 2006;26(16):6082-93.
9. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA. 2006;103(51): 19466-71.
10. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15(10):1109-18.
11. Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting BCR-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463(7280):501-6.
12. Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, et al. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta. 2010;1804(3): 454-62.
13. Iacob RE, Zhang J, Gray NS, Engen JR. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS ONE. 2011;6(1):e15929.
14. Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, and Ruthardt M. p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica 2012; 97(2):251-7.
15. Yang J, Campobasso N, Biju MP, Fisher K, Pan X-Q, Cottom J, et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol. 2011;18(2):177-86.
16. Jahnke W, Grotzfeld RM, Pelle X, Strauss A, Fendrich G, Cowan-Jacob SW, et al. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc. 2010 May 26;132(20):7043-8.
17. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia. 2009;23(12):2242-7.
18. Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, et al. Targeting the SH2-kinase interface in BCR-Abl inhibits leukemo-genesis. Cell. 2011;147(2):306-19.
19. Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell. 2006;21(6):787-98.